The Methodist Hospital

The Methodist Hospital Research Institute

Haifa Shen

Mauro Ferrari

Guodong Zhang

Tong Sun

Jianhua Gu

Rita Elena Serda

Ismail Mustafa Meraz

Xiaoyong Deng

Mingzhen Zhang

Xiaojun Xia

Zhenhua Hu

Jianliang Shen

The present disclosure provides methods and formulations for therapeutic microparticles, wherein formulations are used for administering therapeutic microparticles to subjects by way of intravenous injection. Also, provided are methods of administering therapeutic microparticles to subjects in need thereof. The formulations provide stability and prevent settling and clumping of therapeutic microparticles in solution up to 3 hours.

Microparticle formulations for intravenous therapy and methods for their manufacture and use

Disclosed are biocompatible core/shell compositions suitable for the delivery of populations of mRNA molecules to mammalian cells. The disclosed core-shell structured multicomponent compositions are optimized for the delivery of mRNAs encoding one or more cancer- or tumor-specific antigens to a population of antigen presenting cells, including, for example, human dendritic cells, macrophages and B cells. Also disclosed are methods for use of these compositions as therapeutic cancer vaccines.

Core/shell structure platform for immunotherapy

The present disclosure is directed to a composition for the sustained-release delivery of an active agent to a target cell of an individual. The compositions disclosed herein comprise of at least one porous particle; at least one polymer; and at least one active agent. In an embodiment, the porous particle comprises a plurality of microscale reservoirs. In an exemplary embodiment, the at least one active agent is covalently linked to the at least one polymer to form a polymer-active agent conjugate, and the polymer-active agent conjugate is contained in the plurality of microscale reservoirs of the porous particle. The present disclosure is also directed to a method of treating a tumor, comprising the step of administering to an individual the composition described supra. Additionally, disclosed herein is a method of eliminating tumor stem cells. Furthermore, there is provided a method of circumventing multi-drug resistance in a tumor cell.

Compositions and methods of treating therapy resistant cancer and uses thereof

Disclosed are methods and compositions containing functionalized nanoporous silicon particles, useful in a variety of diagnostic and/or therapeutic regimens for delivery of genetic constructs to one or more cells, tissues, and/or organs of interest. Also provided are methods for introducing into selected host cells one or more selected nucleic acid molecules. The present disclosure is also directed to a method of treating a tumor, comprising the step of administering to an individual one or more of the compositions and formulations thereof as described herein.

Polycation-functionalized nanoporous silicon carrier for systemic delivery of gene silencing agents

Disclosed are mesoporous silicon multi-stage vehicles that comprise liposomal-based second-stage particles, as well as pharmaceutical compositions and formulations including such vectors for use in a variety of diagnostic and therapeutic indications. In particular embodiments, MSV comprising ligand decorated second-stage particles are provided for therapeutic methods including, for example, treatment of mammalian cancers, including those of the human breast.

Growing community of inventors

Bellaire, TX, United States of America

Haifa Shen